Space Station Research Informs New FDA-Approved Cancer Therapy

NASA opens the International Space Station for scientists and researchers, inviting them to use the benefits of microgravity for commercial and public research, technology demonstrations, and more. Today, a portion of the crew’s time aboard station is devoted to private industry, including medical research that addresses complex health challenges on Earth and prepares astronauts for future deep space missions.

In collaboration with scientists at Merck, protein crystal growth research on the space station yielded early insights regarding the structure and size of particles best suited for the development of a new formulation of the company’s cancer medicine pembrolizumab for subcutaneous injection. This new route of delivery was approved by the U.S. Food and Drug Administration in September and offers a time-saving alternative to intravenous infusion for certain patients. These research efforts aboard the space station were supported by the ISS National Laboratory.

For more information, bisit
https://www.nasa.gov/missions/station/iss-research/space-station-research-informs-new-fda-approved-cancer-therapy/